Oculis Holding AG
NASDAQ:OCSBiotechnology
-$0.28 today
- Market cap
- $456.20M
- Beta
- 0.13
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.61
Volume 0.31M
Average 0.65M
OCS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Oculis Holding AGNASDAQ: OCS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of CHF 5M rose 90.2% year over year, ahead of the +63.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 16.0% from the prior quarter. Over 3 fiscal years it compounded at +171.2% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +90.2% holds above the trailing-twelve-month pace of +63.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
CHF · from the cash flow
- Latest · FY2025
- 16.04M CHF
- Year-over-year change
- +64.0%
- 4-year CAGR
- +164.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.04M | +64.0% |
| FY2024 | 2024-12-31 | 9.78M | +171.1% |
| FY2023 | 2023-12-31 | 3.61M | +348.8% |
| FY2022 | 2022-12-31 | 804K | +145.1% |
| FY2021 | 2021-12-31 | 328K | — |
Stock-Based Compensation vs competitors
How OCS compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +63.4% is the highest of 6, against a peer median of -34.4%.
- Stock-based compensation amounts to 3653.8% of revenue for OCS, versus a peer median of 254.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $48.31M USD | +35.8% | +36.5% | 92.8% | |
| LTM Mar 2026 | $31.69M USD | -0.5% | +25.3% | 416.2% | |
| LTM Mar 2026 | CHF 18.42M CHF | +63.4% | +171.2% | 3653.8% | |
| LTM Mar 2026 | $11.78M USD | -34.6% | +16.2% | 4.4% | |
| LTM Mar 2026 | $5.14M USD | -37.3% | +4.9% | 1543.3% | |
| FY2025 | $734.99K USD | -34.4% | -24.7% | — | |
| Peer median (excluding OCS) | — | -34.4% | +16.2% | 254.5% | |
Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (18.52M) | (38.64M) | (88.7M) | (85.94M) | (94.51M) |
| Depreciation & Amortization | 235K | 299K | 287K | 406K | 546K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 328K | 804K | 3.61M | 9.78M | 16.04M |
| Change in Working Capital | (791K) | 6M | (12.99M) | 14.16M | (70.67K) |
| Accounts Receivables | 233K | (152K) | 36K | 247K | 1.9M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 30K | 3.04M | 3.73M | (1.71M) | (1.86M) |
| Other Working Capital | (1.05M) | 3.11M | (16.76M) | 15.62M | (106.97K) |
| Other Non-Cash Items | 4.93M | 6.47M | 43.95M | 14.09M | 15.77M |
| Operating Cash Flow | (13.83M) | (25.07M) | (53.85M) | (47.5M) | (62.22M) |
| Capital Expenditures | (28K) | (3.55M) | (48K) | (230K) | (287.47K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (54.16M) | (17.33M) | (58.05M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (3.48M) | 0 | 0 | 0 |
| Investing Cash Flow | (28K) | (3.55M) | (54.21M) | (17.56M) | (59.38M) |
| Debt Repayment | (98K) | (159K) | (158K) | (274K) | (373K) |
| Common Stock Issued | 0 | 0 | 135.62M | 53.54M | 178.95M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (804K) | (157K) | (5.79M) | 763K | 16.77K |
| Financing Cash Flow | 55.19M | 1.71M | 129.67M | 54.03M | 178.6M |
| Effect of Forex Changes | (16K) | 418K | (3.08M) | 407K | 174.39K |
| Net Change in Cash | 41.33M | (26.49M) | 18.54M | (10.62M) | 57.17M |
| Free Cash Flow | (13.85M) | (28.62M) | (53.89M) | (47.73M) | (62.51M) |
Oculis Holding AG
NASDAQ:OCS
Intrinsic Alpha fair value
Locked
Current Price
$7.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.